Payment overview · 2025
General Payments
$554.41
29 reported records · 13 companies
Healthcare provider profile · identity verified
Andi Qipo, M.D.
Allopathic & Osteopathic Physicians|General Practice · FAIR LAWN, NJ · NPI 1164768461
Verified facts
What the public records show
CMS Open Payments records show Andi Qipo, M.D. received $554.41 in general payments during 2025 across 29 reported records.
Novo Nordisk Inc accounted for 19.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Brilinta by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Ozempic by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $108.72 | 19.6% | 6 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $85.35 | 15.4% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $81.77 | 14.8% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $55.25 | 10.0% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $53.11 | 9.6% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $33.95 | 6.1% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.18 | 4.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.43 | 3.7% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$20.41 | 3.7% | 1 | 2025 |
| Renalytix AI, Inc. | Unresolved — no canonical attribution shown | $19.90 | 3.6% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $18.20 | 3.3% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $17.55 | 3.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.59 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $554.41 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $90.56 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $90.56 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $85.35 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $81.77 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $55.25 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $53.11 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $33.95 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.18 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.43 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $20.41 | 1 | 2025 |
Source payment records
|
|||||
| KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT Normalized: kidneyintelx blood collection convenience kit |
Device | Renalytix AI, Inc. | $19.90 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.54 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 122 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 38 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
122 | 20 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
122 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
38 | 12 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 564 | 137 |
| Amlodipine Besylate | Amlodipine Besylate | 370 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 218 | 53 |
| Metformin Hcl | Metformin Hcl | 195 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 181 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 179 | 49 |
| Gabapentin | Gabapentin | 174 | 40 |
| Levothyroxine Sodium | Levothyroxine Sodium | 173 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 170 | 40 |
| Losartan Potassium | Losartan Potassium | 162 | 46 |
| Lisinopril | Lisinopril | 150 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 146 | 35 |
| Alprazolam | Alprazolam | 140 | 41 |
| Diclofenac Sodium | Diclofenac Sodium | 136 | 37 |
| Eliquis | Apixaban | 128 | 26 |
| Omeprazole | Omeprazole | 126 | 38 |
| Jardiance | Empagliflozin | 122 | 20 |
| Famotidine | Famotidine | 120 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 113 | 40 |
| Carvedilol | Carvedilol | 110 | 30 |
| Furosemide | Furosemide | 110 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 102 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 92 | 20 |
| Finasteride | Finasteride | 92 | 16 |
| Meclizine Hcl | Meclizine Hcl | 86 | 26 |
| Ketoconazole | Ketoconazole | 85 | 23 |
| Levetiracetam | Levetiracetam | 85 | 12 |
| Latanoprost | Latanoprost | 82 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 79 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 76 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 76 | 29 |
| Benztropine Mesylate | Benztropine Mesylate | 70 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 64 | 15 |
| Mirtazapine | Mirtazapine | 64 | 11 |
| Tramadol Hcl | Tramadol Hcl | 64 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 63 | 13 |
| Alendronate Sodium | Alendronate Sodium | 61 | 18 |
| Divalproex Sodium | Divalproex Sodium | 59 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 55 | 14 |
| Nifedipine Er | Nifedipine | 55 | 13 |
| Ammonium Lactate | Ammonium Lactate | 52 | 15 |
| Sertraline Hcl | Sertraline Hcl | 52 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 51 | 18 |
| Linzess | Linaclotide | 51 | 12 |
| Memantine Hcl | Memantine Hcl | 51 | 11 |
| Januvia | Sitagliptin Phosphate | 49 | suppressed |
| Risperidone | Risperidone | 49 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 48 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | 11 |
| Xarelto | Rivaroxaban | 46 | suppressed |
| Xifaxan | Rifaximin | 46 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 45 | 11 |
| Ibuprofen | Ibuprofen | 45 | 18 |
| Simvastatin | Simvastatin | 44 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | 12 |
| Trazodone Hcl | Trazodone Hcl | 42 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 41 | suppressed |
| Allopurinol | Allopurinol | 40 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 40 | suppressed |
| Meloxicam | Meloxicam | 40 | 12 |
| Clonazepam | Clonazepam | 39 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 38 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 38 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 38 | suppressed |
| Ozempic | Semaglutide | 38 | 12 |
| Vascepa | Icosapent Ethyl | 38 | suppressed |
| Azithromycin | Azithromycin | 36 | 28 |
| Haloperidol | Haloperidol | 36 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 36 | suppressed |
| Glimepiride | Glimepiride | 35 | 11 |
| Glipizide Er | Glipizide | 34 | suppressed |
| Naproxen | Naproxen | 34 | 11 |
| Ranolazine Er | Ranolazine | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Lidocaine | Lidocaine | 31 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Olanzapine | Olanzapine | 28 | suppressed |
| Tradjenta | Linagliptin | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 18 |
| Austedo | Deutetrabenazine | 26 | suppressed |
| Ezetimibe | Ezetimibe | 26 | 11 |
| Glipizide | Glipizide | 26 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 26 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 25 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 22 | suppressed |
| Lactulose | Lactulose | 22 | 11 |
| Megestrol Acetate | Megestrol Acetate | 22 | suppressed |
| Prednisone | Prednisone | 22 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Moxifloxacin Hcl | Moxifloxacin Hcl | 20 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 16 |
| Icosapent Ethyl | Icosapent Ethyl | 18 | suppressed |
| Lubiprostone | Lubiprostone | 18 | suppressed |
| Potassium Chloride | Potassium Chloride | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Brilinta | Ticagrelor | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 16 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Movantik | Naloxegol Oxalate | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Novolog | Insulin Aspart | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Tivicay | Dolutegravir Sodium | 15 | suppressed |
| Lumigan | Bimatoprost | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Entacapone | Entacapone | 12 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Mycophenolic Acid | Mycophenolate Sodium | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Clozapine | Clozapine | 11 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 11 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Naftifine Hcl | Naftifine Hcl | 11 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $554.41 · 29 records | Novo Nordisk Inc | AIRSUPRA, AUSTEDO XR, Cologuard Collection Kit, FREESTYLE LIBRE 3, FUROSCIX, IBSRELA, JARDIANCE, KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT, MINIMED 780G, MOUNJARO, Ozempic, Rybelsus, TRELEGY ELLIPTA, Veozah, Wegovy, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error